Scale up isolation of aaptamine for in vivo evaluation indicates its
neurobiological activity is linked to the delta opioid receptor
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Introduction

†These

Opioid receptors belong to the large superfamily of seven transmembrane-spanning (7TM)
G protein-coupled receptors (GPCRs). As a class, GPCRs are of fundamental physiological
importance mediating the actions of the majority of known neurotransmitters and
hormones. The Mu, Delta and Kappa (MOR, DOR, KOR) opioid receptors are particularly
intriguing members of this receptor family as they are the targets involved in many
neurobiological diseases such as addiction, pain, stress, anxiety, and depression. To date
few marine natural products have been investigated for their neurobiological activities.1
One noteworthy example involves ziconotide (1) from the cone snail Conus magnus.2
Compound 1 was the first marine natural product approved by the FDA and is used for the
treatment of pain, marketed under the trade name Prialt® (2004).3 More recently Hamman
reported that aaptamine (2) is the first marine natural product to show in vivo antidepressant activity, however no mechanism of action was proposed.1,4 During a separate
collaborative screening project we profiled 96 sponge-derived extracts and discovered
demethyl–aaptamine (3) and demethyl (oxy) –aaptamine (4) were selective DOR agonists
as shown in Fig. 1. We speculated that the in vivo activity for 2 could thus be linked to the
DOR target and to test this hypothesis we conducted the following experiments below.
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Figure 4. Chemical validation of aaptamine (2) using: a) LC-MS-ELSD analysis with
annotations including m/z ions and b) 1H NMR data of 11308 WB H6.
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Figure 2. Extraction Scheme Flowchart of coll. no. 11308
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Compound-induced intracellular calcium release in HEK-293 cells expressing the DOP receptor. Results are expressed as the mean (± SEM)
relative fluorescence units (RFU; calculated as agonist-induced maximum Ca2+ peak/cell number x 1000) and as (mean ± SEM) percentage of
baseline response (calculated as the ratio of the agonist-induced RFU to that of untreated cells).

Figure 5. Mice were injected with saline or aaptamine (2, 40mg/kg, i.p.) and subjected to:
a forced swim test (a), a locomotor test (b) or a marble burying test (c).
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Experimental and Results
Our first step involved obtaining a source of aaptamine (2) for in vitro and in vivo
evaluation. Compounds 3-4 were obtained from the sponge Aaptos aaptos (coll. no. 92553)
but were devoid of 2. LC-MS analysis of sponge coll. no. 11308 (A. aaptos) indicated m/z
ions of 229 [M+H]+ consistent with that of 2 (not shown). We extracted coll. no. 11308
using a partition scheme shown in Fig. 2. The WB extract was enriched with 2 based on
LC-MS data in Fig. 3a and used to scale up it’s isolation by HPLC shown in Fig. 3b.
Chemical validation of pure 2 was confirmed by LC-MS and 1H NMR data in Fig. 4. This
allowed us to screen 2 alongside 3-4 and confirm it’s DOR activity in vitro. In vivo
evaluation indicated 2 was an antidepressant in wild type mice in the forced swim test (Fig.
5a, black bars) while having no effect on general locomotion (Fig. 5b). We further found
that the antidepressant activity was abolished in genetically modified mice where the DOR
gene was knocked out (Fig. 5a, red bars, DOR KO). We also found 2 was an anxiolytic in
the marble burying test (Fig. 5c). These results indicate the anti-depressant activity
previously reported for 2 is modulated by it’s agonist activity of the delta opioid receptor.

Swim sessions lasted 10min (in ambient light of 580–680lx), and were conducted in individual clear plastic cylinders (35.5cm tall × 25cm in diameter)
filled with water (26.5°C, ±0.7°C) to a depth of 20cm±1.5cm. A camera positioned on an angle to the cylinders recorded the sessions. Manual scoring
was for total immobile time during the last 6min of the session. Immobility was defined as the absence of movement, except that necessary to keep afloat.
Following the swim test, mice were placed in a locomotor chamber to assess general locomotion for 30 minutes. For the marble burying test, mice were
placed in a cage with 5 cm of wood shavings and 15 evenly spaced marbles for 20 minutes. At the end of the session, the number of marbles buried and
exposed were counted. Aaptamine (2) was effective in WT but not DOR knock out (KO) mice (* p<.05 compared to saline).
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Figure 1. a) LC-MS library with annotations including m/z ions and b) comparative
DOP agonist activity of the methanol extract LC fractions of coll. no. 92553 FM.
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Conclusions
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1) Scale up isolation of aaptamine (2) is best achieved through purification of water soluble extracts.
2) The mechanism of action for the in vivo anti-depressant-like and anxiolytic-like activity of 2
is mediated by it’s activity on the delta opioid receptor (DOR).
3) These data suggest that 2 can represent a novel chemical scaffold for the development of new
DOR ligands in neurobiological research.
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Figure 3. a) Analytical traces LC (top) MS (bottom) of coll. no. 11308 WB and
b) Preparative scale up HPLC traces of coll. no. 11308 WB fractions.
Gradient: 10%  100% CH3CN (45 min); [4.0 mg/100 µl] x 30 injections;
λmax = 254 nm; sensitivity = 2.0 AU; flow 2.0 ml/min.
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